SEPN

Over the past six months, Septerna's stock has been influenced by several key events. Positive Phase 1 data for SEP-631 in March 2026, demonstrating good tolerability and dose-dependent inhibition, positively impacted investor sentiment. The initiation of a Phase 1 clinical trial for SEP-479 in April 2026, marked the addition of a second wholly-owned program to its clinical pipeline and was met with positive analyst reiterations and price target increases. Septerna reported its Q4 and full-year 2025 financial results in March 2026, highlighting pipeline progress and reporting a fourth-quarter loss of $0.24 per share, surpassing analyst expectations, and revenue of $24.1 million, largely due to the Novo Nordisk collaboration. Septerna is scheduled to present at the Bank of America Securities Health Care Conference in May 2026, which could generate further investor interest. Analysts have maintained a largely bullish outlook for Septerna, with an average rating of "Moderate Buy" and several price target increases. The global collaboration with Novo Nordisk significantly contributed to Septerna's Q4 2025 revenue and provides financial stability, extending its cash runway into at least 2029. A significant insider purchase by Third Rock Ventures V L.P. indicates strong confidence from a key institutional insider. As of May 1, 2026, the share price was $23.61, representing a significant increase of 229.75% from May 5, 2025, but recent short-term returns have shown mixed moves, with a year-to-date decline of 11.69% as of May 7, 2026.